Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees478
Next Earnings DateN/A
OptionableNot Optionable
Vectura Group (OTCMKTS:VEGPF) Frequently Asked Questions
What is Vectura Group's stock symbol?
Vectura Group trades on the OTCMKTS under the ticker symbol "VEGPF."
Has Vectura Group been receiving favorable news coverage?
Press coverage about VEGPF stock has trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vectura Group earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Vectura Group.
Who are some of Vectura Group's key competitors?
Some companies that are related to Vectura Group include Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Cambrex (CBM), Portola Pharmaceuticals (PTLA), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX) and Prestige Consumer Healthcare (PBH).
Who are Vectura Group's key executives?
Vectura Group's management team includes the folowing people:
- Mr. James Ward-Lilley, CEO & Exec. Director (Age 54)
- Mr. Paul Fry, CFO & Exec. Director
- Mr. Anthony Fitzpatrick, Exec. VP of Operations
- Elizabeth Knowles, VP of Investor Relations
- Mr. John Murphy, Gen. Counsel & Company Sec. (Age 66)
How do I buy shares of Vectura Group?
Shares of VEGPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vectura Group's stock price today?
One share of VEGPF stock can currently be purchased for approximately $1.09.
How big of a company is Vectura Group?
MarketBeat Community Rating for Vectura Group (OTCMKTS VEGPF)
MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote "Outperform" if you believe VEGPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VEGPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
